Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma.

Abstract

Adoptive cell therapy for malignant diseases is showing promise in recent early-phase trials in the treatment of B cell leukemia/lymphoma. Genetically engineered with a tumor-specific chimeric antigen receptor, patient's T cells produce lasting and complete leukemia regression. However, treatment is associated with some toxicity which needs our attention and the field still faces some hurdles at the scientific, technologic and clinical levels. Surmounting these obstacles will establish chimeric antigen receptor T cell therapy as a powerful approach to cure hematologic malignancies, paving the way for the treatment of other common types of cancer in the future.

• Authors: Tobias Riet, Hinrich Abken
• Journal: Expert review of hematology (Expert Rev Hematol) Vol. 8 Issue 4 Pg. 383-5 (Aug 2015) ISSN: 1747-4094 [Electronic] England
• PMID: 25946901 (Publication Type: Editorial, Research Support, Non-U.S. Gov't)

Chemical References

• Receptors, Antigen, T-Cell
• Recombinant Fusion Proteins

Topics

• Humans
• Immunotherapy, Adoptive (adverse effects, methods)
• Leukemia (genetics, immunology, metabolism, therapy)
• Lymphoma (genetics, immunology, metabolism, therapy)
• Receptors, Antigen, T-Cell (genetics, metabolism)
• Recombinant Fusion Proteins (genetics, metabolism)